Asset
ETEPLIRSEN
Sarepta Therapeutics Inc. Common Stock (DE)
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03992430 | phase3 | active_not_recruiting | 2020-07-13 | 2026-10-31 | Sarepta Therapeutics, Inc. | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) |
| NCT03985878 | phase2 | terminated | 2019-06-26 | 2022-08-31 | Sarepta Therapeutics, Inc. | A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995) |
| NCT01396239 | phase2 | completed | 2011-07-01 | 2012-02-01 | Sarepta Therapeutics, Inc. | Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients |
| NCT01540409 | phase2 | completed | 2012-02-27 | 2016-04-15 | Sarepta Therapeutics, Inc. | Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy |
| NCT02286947 | phase2 | completed | 2014-11-01 | 2017-04-21 | Sarepta Therapeutics, Inc. | Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 206488 | NDA | SAREPTA THERAPEUTICS INC |
Marketed products (2)
- EXONDYS 51
- EXONDYS 51